Arcturus Therapeutics’ (ARCT) “Outperform” Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report published on Thursday morning, RTT News reports.

Several other equities research analysts have also recently weighed in on ARCT. Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a buy rating for the company in a research report on Friday, May 10th. Citigroup upped their price objective on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a buy rating in a report on Thursday, February 8th. Finally, HC Wainwright restated a buy rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $64.86.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $30.41 on Thursday. The company has a market capitalization of $818.94 million, a P/E ratio of -7.78 and a beta of 2.65. Arcturus Therapeutics has a one year low of $17.52 and a one year high of $43.81. The business’s 50 day simple moving average is $29.97 and its 200-day simple moving average is $30.99.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. The company had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. On average, sell-side analysts anticipate that Arcturus Therapeutics will post -4.39 EPS for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 17,435 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the sale, the chief operating officer now owns 473,448 shares in the company, valued at $16,580,148.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 13.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently modified their holdings of the stock. SummerHaven Investment Management LLC grew its holdings in Arcturus Therapeutics by 1.7% during the fourth quarter. SummerHaven Investment Management LLC now owns 22,704 shares of the biotechnology company’s stock valued at $716,000 after purchasing an additional 378 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Arcturus Therapeutics by 10.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 428 shares in the last quarter. Formidable Asset Management LLC raised its stake in Arcturus Therapeutics by 3.3% during the 4th quarter. Formidable Asset Management LLC now owns 15,550 shares of the biotechnology company’s stock worth $490,000 after buying an additional 500 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 5.9% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock worth $277,000 after acquiring an additional 606 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Arcturus Therapeutics by 3.0% in the fourth quarter. BNP Paribas Financial Markets now owns 23,259 shares of the biotechnology company’s stock valued at $733,000 after acquiring an additional 682 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.